We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 21.50 | 20.00 | 23.00 | 21.50 | 21.50 | 21.50 | 3,981 | 08:00:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
15 April 2024
Argent BioPharma Ltd.
Dr. Shlomo Sadoun Joins Argent BioPharma Ltd Advisory Board
Argent BioPharma Ltd (Argent BioPharma or the Company), an innovative drug discovery company within the biopharmaceutical sector, is pleased to announce Dr. Shlomo Sadoun has joined Argent BioPharma's advisory board with immediate effect.
Dr. Shlomo Sadoun has over 18 years of experience in the pharmaceutical sector. Dr. Sadoun co-founded and leads SK-Pharma Group, a global pharmaceutical company operating in 18 countries. SK-Pharma specialises in producing and marketing generic, specialty pharma, hybrid generics, and biosimilar pharmaceutical products. Additionally, Dr. Sadoun serves as the CEO of Arphio, an orphan drug company utilising proprietary technology to promote, market, and sell orphan drugs worldwide.
Dr. Sadoun's expertise lies in leveraging technology to redefine business processes. He has established strategic alliances with over 200 innovative companies and launched more than 300 products globally, many of which were pioneering and branded. Dr. Sadoun's adeptness in utilising technological advancements has propelled SK-Pharma to become the fastest-growing pharmaceutical group in Israel and beyond. Dr. Sadoun holds a master's degree in Global Management from Salford University and a Doctorate in Business Administration from the Royal Academy of Economics and Technology in Switzerland, with a focus on public health.
Roby Zomer, Managing Director and CEO of Argent BioPharma, commented: "We are delighted to welcome Dr. Shlomo Sadoun, an esteemed addition to our advisory board. With his wealth of experience and expertise in the pharmaceutical sector, Dr. Sadoun will undoubtedly provide invaluable insights and guidance as we embark on our new strategic direction. His appointment reaffirms our commitment to fostering a diverse and knowledgeable advisory board, dedicated to driving innovation and growth in our Company."
-Ends-
Authorised for release by the board of directors, for further information please contact:
Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6382 3390
|
Argent BioPharma Rowan Harland Company Secretary +61 8 6382 3390 |
UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 |
UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |
About Argent BioPharma
Argent BioPharma is dedicated to meeting unmet medical needs by combining PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader in the biopharmaceutical sector. Our mission centres on researching and developing ground-breaking treatments for worldwide health issues, guided by strategic principles such as pioneering life science advancements, ensuring global access, fostering continuous innovation, and striving for industry leadership.
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions